FORT LAUDERDALE, Fla., Feb. 11, 2016 -- OmniComm Systems, Inc. (OmniComm) (OTCQX:OMCM), a global leading provider of clinical data management technology, today announced the signing of a five year agreement with a Canadian pharmaceutical drug developer. OmniComm’s TrialMaster electronic data capture (EDC) suite will be used for the collection of clinical data during this five year term in numerous global trials spanning Phase I to Phase III clinical studies.
TrialMaster was selected after an exhaustive evaluation that included OmniComm and six other leading EDC solution providers to select the replacement for their legacy EDC application. Specific evaluation emphasis was placed on fast study build time, ease of data extraction in submission ready data format, direct patient data entry and a comprehensive feature set. TrialMaster was found superior in all categories when compared to the other six competing EDC technologies. The depth and breadth of functionality, ease of contracting, and a highly responsive executive management team were significant factors in the selection of TrialMaster EDC.
Trial build time was of particular interest as this clinical development team will be responsible for building their own studies. They found TrialMaster’s rich and versatile design and build toolset easier to learn and easier to work with when compared to the competing technologies and thereby enabling faster study build times. TrialMaster will be deployed within OmniComm’s OmniCloud® for hosting and maintenance of the entire IT infrastructure, ensuring clinical data management technology is always running; data is secure, and product enhancements are rolled out seamlessly.
“We are very pleased that, across a field of highly regarded EDC technologies, OmniComm’s TrialMaster was selected as the best solution by a very knowledgeable and savvy group of clinical professionals,” states Kuno van der Post, SVP of business development, OmniComm. “We are all extremely excited to see this new client showcase our software.”
Supporting Information
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.omnicomm.com.
Trademarks
OmniComm, OmniCloud, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
OmniComm Systems, Inc. 2101 West Commercial Blvd. Suite 3500 Fort Lauderdale, FL 33309 USA Phone: +1.954.473.1254 Fax: +1.954.473.1256 www.omnicomm.com


LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 



